The ACT program is a CPRIT funded accelerator launched in collaboration with the Gulf Coast Consortium (GCC) and the University of Texas Medical Branch (UTMB) to support Texas-based biotech entrepreneurs, researchers contemplating translations, and internal comprehensive drug development programs. TMC ACT is the only cancer therapeutics accelerator building relationships with health care professionals leading the world’s best cancer treatment programs at the Texas Medical Center member hospitals.
ACT participants will gain insight into every facet of managing a cancer therapeutics company including developing and incorporating an integrated strategic plan that guides their company’s business and drug development efforts. ACT will simultaneously provide Texas researchers and startup companies with integrated training, resources, and mentoring in order to help advance innovative cancer therapy discoveries and development programs, ultimately leading to new approaches and therapies for cancer patients.
